Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Selectis Health (GBCS) EBITDA Margin (2017 - 2025)

Selectis Health's EBITDA Margin history spans 14 years, with the latest figure at 0.62% for Q3 2025.

  • For Q3 2025, EBITDA Margin rose 859.0% year-over-year to 0.62%; the TTM value through Sep 2025 reached 0.42%, up 999.0%, while the annual FY2024 figure was 6.91%, 1292.0% up from the prior year.
  • EBITDA Margin for Q3 2025 was 0.62% at Selectis Health, up from 0.84% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 24.78% in Q1 2021 and bottomed at 27.84% in Q4 2023.
  • The 5-year median for EBITDA Margin is 2.87% (2024), against an average of 3.19%.
  • The largest annual shift saw EBITDA Margin tumbled -3958bps in 2021 before it surged 2691bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 7.02% in 2021, then plummeted by -30bps to 9.15% in 2022, then tumbled by -204bps to 27.84% in 2023, then surged by 97bps to 0.94% in 2024, then soared by 167bps to 0.62% in 2025.
  • Per Business Quant, the three most recent readings for GBCS's EBITDA Margin are 0.62% (Q3 2025), 0.84% (Q2 2025), and 0.56% (Q1 2025).